Yousif Capital Management LLC Has $2.73 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Yousif Capital Management LLC lessened its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 27.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,152 shares of the medical equipment provider's stock after selling 14,707 shares during the quarter. Yousif Capital Management LLC's holdings in Hologic were worth $2,726,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Victory Capital Management Inc. boosted its stake in shares of Hologic by 8.9% in the 3rd quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider's stock valued at $335,763,000 after buying an additional 393,371 shares during the period. TD Asset Management Inc lifted its stake in Hologic by 7.7% during the third quarter. TD Asset Management Inc now owns 1,845,462 shares of the medical equipment provider's stock worth $128,075,000 after purchasing an additional 131,999 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Hologic by 9.0% during the third quarter. Hsbc Holdings PLC now owns 1,721,339 shares of the medical equipment provider's stock worth $119,472,000 after purchasing an additional 141,542 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Hologic by 2.9% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 1,634,362 shares of the medical equipment provider's stock worth $115,586,000 after purchasing an additional 45,785 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in Hologic by 4.5% during the third quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider's stock worth $113,077,000 after purchasing an additional 69,494 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $0.86 during trading on Tuesday, reaching $75.77. The company had a trading volume of 1,515,828 shares, compared to its average volume of 1,754,271. The firm has a market capitalization of $17.79 billion, a price-to-earnings ratio of 35.91, a price-to-earnings-growth ratio of 2.57 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The stock's fifty day moving average price is $76.08 and its 200 day moving average price is $72.88. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.03. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company's revenue for the quarter was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 earnings per share. As a group, equities research analysts predict that Hologic, Inc. will post 4.01 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the subject of several recent analyst reports. UBS Group boosted their target price on Hologic from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Friday, February 2nd. StockNews.com cut Hologic from a "buy" rating to a "hold" rating in a research note on Friday, March 8th. Evercore ISI boosted their target price on Hologic from $76.00 to $78.00 and gave the stock an "in-line" rating in a research note on Thursday, April 4th. Raymond James boosted their price objective on Hologic from $85.00 to $88.00 and gave the company an "outperform" rating in a research note on Friday, February 2nd. Finally, William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Hologic currently has an average rating of "Hold" and a consensus price target of $87.00.

Insider Buying and Selling

In related news, Director Scott T. Garrett sold 16,441 shares of the company's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company's stock, valued at $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Charles J. Dockendorff sold 1,465 shares of the company's stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares of the company's stock, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the business's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.